Advances in Disease-Modifying Therapies for Parkinson's

• DOI: https://doi.org/10.22533/at.ed.1594902408107

• Palavras-chave: Parkinson's disease; Disease-modifying therapies; Neuroprotection; Neurodegeneration; Dopaminergic pathways

• Keywords: Parkinson's disease; Disease-modifying therapies; Neuroprotection; Neurodegeneration; Dopaminergic pathways

• Abstract:

  Parkinson's Disease (PD) was identified in 1817 by James Parkinson and later named after Jean-Martin Charcot. It is a progressive neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra, resulting in motor symptoms such as rigidity, bradykinesia and resting tremor, as well as neuropsychiatric manifestations [1,2]. Although there are treatments to relieve symptoms, there are no therapies that modify the course of the disease. The challenges to developing such therapies include the multifactorial nature of PD, the heterogeneity of symptoms between patients and the lack of reliable biomarkers [3].
  The review of the scientific literature focused on PD-modifying therapies, with an emphasis on an evidence-based approach. Strategies investigated include immunotherapy to reduce α-synuclein, modulation of inflammation, treatments for GBA gene mutations and LRRK2 inhibitors. Agents targeting calcium and iron balance have also been explored, as well as interventions to improve mitochondrial function [4].
  The study concludes that it is vital to integrate different areas of health to understand PD, considering its complexity and the need for personalized therapeutic approaches. Advances in the objective quantification of response to treatment and research into biomarkers could revolutionize the management of PD, allowing for more effective and targeted interventions [5].